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March 21, 2006:1226–38ho had a positive family history, not included? Did any of these
elatives suffer from a neuromuscular disorder? According to which
ype was LVHT transmitted in the families?
Moreover, which neuromuscular disorder was diagnosed in
atient #7? Did the patient undergo only clinical neurological
nvestigations or were invasive procedures also carried out? Were
hrombi detected in any of the investigated patients, particularly in
atient #5, who had systemic embolism?
Also, how to explain the pathomechanism of acquired LVHT,
here the myocardium was once totally compact? In these cases,
athogenetic explanations other than noncompaction of the em-
ryonic myocardium are required.
In conclusion, the distinction between “normal” and “abnormal”
rabeculation is a continuing challenge. Commonly accepted diag-
ostic criteria for LVHT should be developed based on the
orrelation of pathoanatomical and imaging findings. The diagno-
is of LVHT relies on morphological abnormalities and does not
equire a positive family history, neuromuscular disorders, embo-
ization, or regional wall motion abnormalities as additional
iagnostic criteria.
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EPLY
e thank Drs. Stöllberger and Finsterer for their interest in our
eport (1). Many of the questions they raise reflect concern with
ow we selected our study population. Their suggestion of enroll-
ng only symptomatic patients, however, with subsequent access to
athoanatomical specimens in order to establish diagnostic criteria
ould heavily bias findings to the severe end of the spectrum.
Concerns raised by Drs. Stöllberger and Finsterer do not
ecognize that the likelihood of any individual with a ratio of
hicknesses between the trabecular and compact myocardium
2.3:1 suffering from pathological noncompaction, when ex- cressed as the posterior probability, depends on the pretest
robability or prevalence. A patient with a known family history of
oncompaction and a 1 in 2 chance of having inherited the
ondition in autosomal dominant fashion would have a 97%
hance of suffering from pathological noncompaction. In contrast,
iven the estimated prevalence of significant noncompaction of 1
n every 2,000 members of the normal population (2), the posterior
robability would only be 26%. This Bayesian calculation (3)
xemplifies the importance of taking into account the pretest
robability, especially in diseases with relatively low prevalence.
We included one patient with left ventricular noncompaction
n the basis of marked electrocardiographic changes, a family
istory of left ventricular noncompaction, and a distinct bilaminar
ppearance of the trabeculated and compacted layers of the
yocardium. Based on imaging findings alone, this patient would
ot have been diagnosed with left ventricular noncompaction.
nterestingly, this patient very recently developed symptomatic
ardiac failure. This patient, now with clinical evidence of disease,
ut in the face of an initially nondiagnostic ratio between the
rabecular and compacted layers, must now be assumed partially to
xpress the disease, whereas a healthy volunteer with a low pretest
robability would be interpreted as having nonpathological non-
ompaction.
We agree that the pathophysiological mechanisms leading to
eft ventricular noncompaction are not fully understood. Our data
n the segmental distribution of trabeculated myocardium, none-
heless, support the hypothesis of an early arrest during the
mbryological process of compaction.
Our experience is that trabeculations can be more readily
isualized in the relaxed heart. Magnetic resonance imaging (MRI)
llows easy delineation of the epicardial border in both systole and
iastole, in contrast to echocardiography, with poor epicardial
elineation in diastole. State-of-the-art sequences, such as steady-
tate free precession, are not prone to flow artifacts, as once seen
ith the older sequences employing gradient echo techniques. The
ew sequences permit clear distinction between the trabeculations
nd the compacted myocardium. This makes this imaging tech-
ique ideal to distinguish noncompaction from papillary muscles,
alse tendons, and aberrant bands, because it has the accuracy to
ermit analysis of the entirety of the ventricular mass. We are
urprised that Drs. Stöllberger and Finsterer raise this point as it is
idely acknowledged that MRI, unlike echocardiography, does
ot suffer from this caveat.
Because of the constraints of space, we can only answer some of
he further enquiries concerning the patients studied. An apical
hrombus was detected by contrast-enhanced MRI in the patient
ith a history of systemic embolism. We enrolled all first-degree
embers of our families with left ventricular noncompaction who
greed to participate in the study and to undergo screening. None
f our patients, including the seventh patient, had a family history
f neuromuscular disorders. Our patients with left ventricular
oncompaction and a positive family history showed an autosomal
ominant pattern of transmission.
In conclusion, our study demonstrated the high diagnostic
ccuracy of cardiovascular MRI for left ventricular noncompaction.
wing to the importance of pretest probabilities, we disagree with
he view that the diagnosis of left ventricular noncompaction
hould rely exclusively on morphological abnormalities. Thus,
ssessments using either echocardiography or cardiovascular MRI
an at best contribute to the clinical diagnosis.
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ole of Adenosine in
cute Myocardial Infarction
he Acute Myocardial Infarction STudy of ADenosine (AMISTAD
I) is a pivotal trial having major clinical implications for the
reatment of patients with acute myocardial infarction (AMI) (1).
he AMISTAD II study corroborates the findings of the first
MISTAD study (2); it verifies that, as in animals (3), myocardial
eperfusion injury significantly contributes to final infarct size in
umans, and demonstrates that reperfusion injury accounts for
50% of the final infarct size after reperfusion.
Several issues regarding the design of the AMISTAD II study
hould be addressed. First, the study was severely underpowered.
his was further compounded by having a second treatment arm
ith low-dose adenosine. The rationale for the second arm is
nclear as the first AMISTAD study clearly shows that high-dose
denosine (70 g/kg/min) is efficacious with regard to reducing
nfarct size in patients with anterior AMI and does not cause
erious adverse clinical events (2).
Second, because the beneficial effects of adenosine in experi-
ental models occur only with reperfusion, adenosine should
ttenuate reperfusion injury only in reperfused patients. In the
MISTAD II study approximately 60% of the patients were
reated with thrombolytic agents, with streptokinase used in
lmost 40% of these patients. This would result in only approxi-
ately 80% of patients undergoing successful reperfusion. A subset
nalysis of the primary clinical end points in the high-dose group
ho underwent successful reperfusion may show a significant
ifference. This hypothesis is supported by the observation, pre-
ented in abstract form, that the combined clinical end point of
eath and congestive heart failure was significantly reduced in the
ooled adenosine group (low  high dose) who underwent
5uccessful reperfusion (placebo 15% vs. pooled adenosine 11%; p
.04), whereas no significant difference was found in patients who
id not reperfuse (placebo 34% vs. pooled adenosine 33%; p 0.7)
4).
Third, because animal studies demonstrate that adenosine’s
eneficial effects are lost if myocardial ischemia occurs for more
han 3 h (5), adenosine would prevent reperfusion injury only in
atients receiving adenosine within the first 3 h after coronary
cclusion. Therefore, a subset analysis of the high-dose group who
ere reperfused within 3 h may yield an even greater reduction in
linical end points. Indeed, data from the abstract presentation
how strong trends in the combined end points in the pooled
denosine group treated within 2 h of symptoms (pooled adenosine
% vs. placebo 13%) (4). This is further supported by the study of
arzilli et al. (6) in which patients undergoing mechanical
eperfusion within 2 h of symptoms and who were treated with
denosine showed a significant improvement in ventricular func-
ion and a reduction in major adverse clinical end points.
Despite these shortcomings, the AMISTAD II study, taken in
onjunction with other clinical studies with adenosine, has impor-
ant implications for the treatment of AMI. Adenosine is the only
gent that has been shown consistently to reduce infarct size and,
n some studies, to improve clinical outcomes in AMI patients
ndergoing reperfusion therapy. Adenosine should therefore be
dded to the armamentarium of agents used to treat patients with
MI who are candidates for either pharmacologic or mechanical
eperfusion strategies.
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lease note: Vanderbilt University owns intellectual property related to adenosine
nd myocardial infarction that was invented by Drs. Forman and Jackson some
5 years ago.
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